Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF - Get Free Report) reached a new 52-week high during trading on Thursday . The company traded as high as $26.50 and last traded at $26.50, with a volume of 881 shares. The stock had previously closed at $24.59.
Wall Street Analysts Forecast Growth
Separately, Royal Bank of Canada upgraded shares of Hikma Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a report on Tuesday, December 10th.
Check Out Our Latest Analysis on Hikma Pharmaceuticals
Hikma Pharmaceuticals Stock Up 7.8 %
The company has a quick ratio of 0.98, a current ratio of 1.66 and a debt-to-equity ratio of 0.46. The stock's fifty day simple moving average is $24.27 and its 200 day simple moving average is $24.77.
Hikma Pharmaceuticals Company Profile
(
Get Free Report)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
